High in the Peruvian Andes, a shaman rubs a fluffy white rabbit all over Chris Kilham's body, murmuring in Quechua, the language of these barren plains. Then she slits the animal's throat and lets the blood run into a tiny grave.
To Kilham, the offering -- an appeal to the gods for a bountiful harvest of maca, a local tuber -- is just another day at the office.
Part Sir David Attenborough, part Indiana Jones, Kilham, an ethnobotanist from Massachusetts who has dubbed himself the Medicine Hunter, has scoured remote jungles and highlands for three decades for plants, oils and extracts that can heal. He has eaten bees and scorpions in China, shot blowguns with Amazonian natives, and learned traditional war dances from Pacific Islanders.
ILLUSTRATION: MOUNTAIN PEOPLE
But behind the colorful tales lies the prospect of money, lots of money -- for Western pharmaceutical companies, impoverished indigenous tribes, and Kilham.
Products that once seemed exotic, like ginseng, ginkgo biloba or aloe vera, now roll off the tongues of Westerners. All told, natural plant substances generate more than US$75 billion in sales each year for the pharmaceutical industry, another US$20 billion in herbal supplement sales and around US$3 billion in cosmetics sales, a study by the European Commission showed.
Although the efficacy of some of the products the herbal ingredients go into is hotly debated, their popularity is not in doubt. Thirty-six percent of adults in the US use some form of what experts call complementary and alternative medicine, CAM for short, according to a 2004 study published by the National Center for Complimentary and Alternative Medicine, a division of the National Institutes of Health.
Kilham believes multinational drug companies underutilize the medicinal properties in plants.
They pack pills with man-made compounds and sell them at huge markups, he says. He wants Westerners to use the pure plant medicines that indigenous peoples have used for thousands of years.
"People in the US are more cranked up on pharmaceutical drugs than any other culture in the world today," Kilham said. "I want people using safer medicine. And that means plant medicine."
Easygoing and earnest, Kilham, 55, caught the plant bug after taking an herb walk at an organic farm in Natick, Massachusetts, in 1971.
A self-confessed hippie, he was already into "yoga, natural foods and meditation," and the discovery that plants had medicinal properties had a profound effect. He created a course in holistic health at the University of Massachusetts, where he is now on the faculty, and made his first overseas trip -- to India -- to track down exotic flora.
Now he can identify unusual plants by their Latin names and he proudly regales the uninitiated on their individual properties. Shortly after leaving Lima on a trip taking French businessmen to the Peruvian Andes, he stopped the van and enthusiastically explained how the tropane alkaloids in a dusty plant he spotted by the side of the road are used by ophthalmologists to dilate pupils for eye examinations.
Such properties are often well known by indigenous peoples. So-called bioprospectors can make their fortunes by bringing those advantages to the attention of companies who identify the plant's active compound and use it as a base ingredient for new products that they patent.
Some 62 percent of all cancer drugs approved by the US Food and Drug Administration come from such discoveries, according to a study by the UN University, a scholarly institution affiliated with the UN.
"Latin American nations, especially Amazonian nations, have extremely rich and diverse flora, so the potential for commercial applications appears great," said Tony Gross, a Brazil-based researcher at the university. "They say that in one in 10,000 you get something interesting. So it is not a gold mine, but when you do hit on something that does become a market leader you can make enormous amounts of money from it."
In Peru, Kilham is betting on maca, a small root vegetable that grows here in the central highlands -- "a turnip that packs a punch," he says, adding "it imparts energy, sex drive and stamina like nothing else."
That view is supported by studies carried out at the International Potato Center, a Lima-based research center that is internationally funded and staffed. Studies there show maca improves stamina, reduces the risk of prostate cancer and increases the motility, volume and quality of sperm.
Some peer-reviewed studies published in the journal Reproductive Biology and Endocrinology backed up those findings.
For centuries, maca has been a revered crop in this austerely beautiful region 250km northeast of Lima. Inca warriors ate it before going into battle. Later, Peruvians used it to pay taxes to Spanish conquistadors.
Today, locals consume it boiled alongside dried vicuna meat in soups; or diced with carrots, peas and cauliflowers in salads. Maca flour is used to make sponge cake. Flavored with chocolate, it is made into maca puffs. Villagers offer visitors maca juice; airports sell maca toffees.
Kilham first heard about the tuber in 1996. Two years later, he went to Peru to find out more. There he formed a partnership with Sergio Cam, a Peruvian entrepreneur who invested much of the money he made as a construction worker in California from 1984 to 1999 to start Chakarunas Trading. The company is named after the Quechua word for men who build bridges between cultures.
Today, Chakarunas organizes local growers to sell their maca to the French firm Naturex, which extracts it into concentrate. Naturex sells the concentrate to Enzymatic Therapy, a Wisconsin-based company that makes and markets the finished maca products.
Thanks to the health supplements boom, both companies have grown, with Naturex's revenues topping US$125 million last year and Enzymatic Therapy's surpassing US$80 million. Enzymatic Therapy sells US$200,000 worth of maca-based products each month, company chief executive Randy Rose said.
One product, Maca Stimulant, is sold in Wal-Mart under Kilham's Medicine Hunter brand. Kilham earns a retainer from both Naturex and Enzymatic Therapy, in addition to royalties from another Medicine Hunter-branded product at Wal-Mart.
Kilham says he earns around US$200,000 each year in retainers, and sales are so buoyant he expects to make "in the mid-six figures" in royalties next year.
Kilham insists he is not in the business simply for financial gain. His motivation comes from promoting herbal medicines and helping traditional communities, he said.
"I have financial security and don't need to make money from this," he said. "I believe trade is the best way to get good medicines to the public, to help the environment and to help indigenous people."
He and Cam pay growers in Ninacaca a premium of 6 soles (about US$2) per kilo of maca, almost twice the going rate of 3 to 3.40 soles per kilo. They have set up a computer room at the Chakarunas warehouse and a free dental clinic, the town's first.
Kilham is clearly adored by the locals in these desolate, wind-swept villages. On a recent visit here, shamans, maca growers and their families flocked to him. Since only maca and potatoes grow at this altitude, the locals are thankful Kilham is helping them sell their produce.
He makes a point of returning regularly to Peru to affirm his commitment to the project. On this trip, his third this year, he brought executives from Phythea, a French company that sold 40 million euros (US$58.8 million) worth of natural products last year. Phythea's president, Laurent Mallet, had heard about maca and wanted to see both the agricultural and social aspect of Chakarunas Trading up close.
Mallet said he was so touched by the people and the rawness of their surroundings -- it took him seven hours by van to get here, and several doses of oxygen to offset the headaches and nausea brought on by the altitude -- that he vowed to increase his order of maca from 4.5 tonnes to 23 tonnes this year if clinical trials in Bordeaux confirmed that maca reduces hot flushes and night sweats in menopausal women.
"I think it could be a very good product for us," Mallet said. "I especially like the human dimension. They want to build a school and a medical center."
To be sure, not everyone is so positive. Kilham runs the constant risk of being branded a "biopirate," an outsider who steals traditional knowledge and fails to pass on the benefits to the local community.
In 2001, the company Kilham worked for at the time, Pure World Botanics, obtained US patents for isolating and extracting maca's key active compounds.
The Peruvian government accused the company of profiting from what was rightfully Peru's.
Kilham said he fought to make his bosses open up the patents.
The company denied they had acted improperly but Naturex, which bought Pure World Botanics in 2005, granted Peruvian companies free licenses to the patents and vowed to increase the price paid per kilo to maca farmers by 15 percent.
"At Naturex," the company's marketing manager, Antoine Dauby, said in a statement, "we believe in giving back to the communities where we do business. And we're doing that in Peru."
Could Asia be on the verge of a new wave of nuclear proliferation? A look back at the early history of the North Atlantic Treaty Organization (NATO), which recently celebrated its 75th anniversary, illuminates some reasons for concern in the Indo-Pacific today. US Secretary of Defense Lloyd Austin recently described NATO as “the most powerful and successful alliance in history,” but the organization’s early years were not without challenges. At its inception, the signing of the North Atlantic Treaty marked a sea change in American strategic thinking. The United States had been intent on withdrawing from Europe in the years following
My wife and I spent the week in the interior of Taiwan where Shuyuan spent her childhood. In that town there is a street that functions as an open farmer’s market. Walk along that street, as Shuyuan did yesterday, and it is next to impossible to come home empty-handed. Some mangoes that looked vaguely like others we had seen around here ended up on our table. Shuyuan told how she had bought them from a little old farmer woman from the countryside who said the mangoes were from a very old tree she had on her property. The big surprise
The issue of China’s overcapacity has drawn greater global attention recently, with US Secretary of the Treasury Janet Yellen urging Beijing to address its excess production in key industries during her visit to China last week. Meanwhile in Brussels, European Commission President Ursula von der Leyen last week said that Europe must have a tough talk with China on its perceived overcapacity and unfair trade practices. The remarks by Yellen and Von der Leyen come as China’s economy is undergoing a painful transition. Beijing is trying to steer the world’s second-largest economy out of a COVID-19 slump, the property crisis and
As former president Ma Ying-jeou (馬英九) wrapped up his visit to the People’s Republic of China, he received his share of attention. Certainly, the trip must be seen within the full context of Ma’s life, that is, his eight-year presidency, the Sunflower movement and his failed Economic Cooperation Framework Agreement, as well as his eight years as Taipei mayor with its posturing, accusations of money laundering, and ups and downs. Through all that, basic questions stand out: “What drives Ma? What is his end game?” Having observed and commented on Ma for decades, it is all ironically reminiscent of former US president Harry